Completed Research Grants

2016	Consensus conference for the revision of the diagnostic criteria of PSP	Dr.	Guenter	Hoeglinger	Klinikum rechts der Isar der TU Muenchen, Munich, Germany
2014	Elucidating PSP Genotype-Phenotype Relationships Using Human Isogenic iPSCs	Dr.	John	Steele	University of California, San Diego, CA
2014	Synaptic Tau-Proteasome Dysfunction and a Potential Therapeutic Strategy	Dr.	Natura	Myeku	Columbia University, New York, NY
2013	Epigenetic Modifications in PSP	Dr.	Ulrich	Mueller	University of Giessen, Germany
2014	Spreading of a Synuclein Pathology in Multiple System Atrophy	Dr.	Johannes	Brettschneider	University of Ulm, Germany
2014	Selective Cell Vulnerability in MSA	Dr.	Eduardo	Benaroch	Mayo Clinic , Jacksonville, FL
2013	Urso Student Fellowship	Mr.	John	Titus	Duke University Medical Center, Durham, NC
2013	The Role of O-Linked Protein Glycosylation in the Spread of Tau Pathology	Dr.	Christoph	Wiessner	Asceneuron SA, Switzerland
2013	Altering Tau Splicing for PSP and Other 4R Tauopathies	Dr.	Michael	Wolfe	Harvard Medical School, Boston, MA
2013	Follow-Up Genotyping & Functional Analysis of PSP H1 Haplotype Variants	Dr.	Pau	Pastor	Foundation for Applied Medical Research, Pamplona, Spain
2013	Eloise H. Troxel Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic , Jacksonville, FL
2013	Urso Student Fellowship	Mrs.	Emily	Beiser	Rutger University, New Brunswick, NJ
2013	Mechanisms and Therapy for Tauopathy based on RNA Binding Proteins	Dr.	Benjamin	Wolozin	Boston University, Boston, MA
2013	Tau Dimerization: A Mechanism of Tau Function and Dysfunction?	Dr.	Stuart	Feinstein	University of California, Santa Barbara, CA
2012	PSP Whole Exome Study Phase Two	Dr.	Gerad	Schellenberg	University of Pennsylvania, Philadelphia, PA
2012	Splice Variant Markers for PSP	Dr.	Judith	Potashkin	Rosalind Franklin University of Medicine and Science
2012	Eloise H. Troxel Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic , Jacksonville, FL
2012	Tracking Progressive Neurodegeneration in PSP Using Diffusion Tensor MRI	Dr.	Massimo	Filippi	Vita-Salute San Raffaele University, Milan, Italy
2012	Identifying Functional Genetic Risk Factors for PSP by RNA-seq	Dr.	Nilufer	Ertekin-Taner	Mayo Clinic, Jacksonville, FL
2012	Gene Expression and Neuropathology Endophenotypes for Gene Discovery in PSP	Dr.	Nilufer	Ertekin-Taner	Mayo Clinic, Jacksonville, FL
2012	Mechanisms of Tau and ER Stress for Novel PSP and CBD Therapeutics	Dr.	Jose	Abisambra	University of South Florida, Tampa, FL
2012	An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to the AL-108-231 of Davunetide for the Treatment of Non-PSP Predicted Tauopathies: CBD, Progressive Nonfluent Aphasia and FTD with Parkinsonism Linked to Chromosome 17	Dr.	Adam	Boxer	University of California, San Francisco, CA
2012	PSP Whole Exome Study	Dr.	Gerard	Schellenberg	University of Pennsylvania, Philadelphia, PA
2011	Eloise H. Troxel Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic, Jacksonville, FL
2011	Models to Determine the Toxicity of Tau Aggregates	Dr.	Chris	Gamblin	University of Kansas, Lawrence, KS
2011	Evaluating Reduced Tau Levels as a Therapy for PSP and CBD	Dr.	Timothy	Miller	Washington University School of Medicine, St. Louis, MO
2011	Epigenetic Modifications in PSP	Dr.	Ulrich	Mueller	University Hospital Giessen & Marburg, Giessen, Germany
2011	CHIP-Mediated Regulation of Hsp90 High Affinity Complex	Dr.	Leonard	Petrucelli	Mayo Clinic, College of Medicine, Jacksonville, FL
2011	Manipulating the Substrate Specificity Program in the Chaperone System to remove Tau in PSP and CBD	Dr.	Chad	Dickey	University of South Florida, Tampa, FL
2010	A Pilot Clinical Trial of NAP (AL-108) for CBD and Frontotemporal Lobar Degeneration with Predicted CBD Pathology	Dr.	Adam	Boxer	Regents of the University of California, San Francisco, CA
2010	Pathogenetic Mechanisms of Progressive Supranuclear Palsy and Corticobasal Degeneration	Dr.	Gerard	Schellenberg	University of Pennsylvania, Philadelphia, PA
2010	PSP/CBD Genome-Wide Association Analysis follow-up and replication	Dr.	Gerard	Schellenberg	University of Pennsylvania, Philadelphia, PA
2010	Eloise H. Troxel Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic, Jacksonville, FL
2010	Tau and its Pathology in Neurons derived from Induced Pluripotent Stem Cells of FTDP-17T Patients with PSP-Like Tau Pathology	Dr.	Maria	Spillantini	University of Cambridge, Cambridge, UK
2010	Autophagic Modulation and Clearance of Tau Aggregates	Dr.	Ho	Yu	Columbia University Medical Center, New York, NY
2009	Modeling Haplotype-Specific Gene Function at the MAPT Locus in 4R Tauopathy	Dr.	Richard	Wade-Martins	University of Oxford, Oxford, UK
2009	Inhibition of Tau Pathology in Transgenic Mouse Models with an Optimized Orally Active Tau Kinase Inhibitor	Dr.	Hanno	Roder	TauTaTis, Inc, Jacksonville, FL
2009	MicroRNA Regulation of MAPT in CBD and Related Tauopathies	Dr.	Rosa	Rademakers	Mayo Clinic Jacksonville, FL
2009	Structural Polymorphism of Tau Filaments in CBD	Dr.	Martin	Margittai	University of Denver, Denver, CO
2009	Comparative Proteomics of CBD & PSP Brain to Identify Biomakers	Dr.	Shu-Hui	Yen	Mayo Clinic, Jacksonville, FL
2009	Development of Activators of Puromycin Sensitive Aminopeptidase to Treat CBD	Dr.	Stanislav	Karsten	Los Angeles Biomedical Research Institute, Torrance, CA
2009	Tau-Mediated Effects Upon Microtubule Structure and Kinesin Translocation	Dr.	Stuart	Feinstein	Regents of the University of California, Santa Barbara, CA
2009	In Vivo Identification of Pharmacological Treatments for Tauopathy	Dr.	Mel	Feany	Brigham and Women’s Hospital, Boston, MA
2009	HSP-Peptide Complex Mediated Immunization in a Mouse Model of Tauopathy	Dr.	Michael	DeTure	Mayo Clinic Jacksonville, FL
2009	Genomewide Identification of Transregulators of Tau Gene Expression & Splicing	Dr.	Rohan	deSilva	Institute of Neurology, UCL,  Queen Square, London
2009	A Pilot Clinical Trial of NAP (AL-108) for CBD and Frontotemporal Lobor Degeneration with Predicted CBD Pathology	Dr.	Adam	Boxer	Regents of the University of California, San Francisco, CA
2009	Polyphenols from Grape Seeds as a Potential Therapeutic Agent in Taupathies	Dr.	Giulio	Pasinetti	Mount Sinai School of Medicine, New York, NY
2009	The Effects of CBD-Associated Tau Gene H1 Haplotype on Tau Expression	Dr.	Hana	Dawson	Duke University Medical Center, Durham, NC
2009	Targeting Hsp70 as a Therapeutic Strategy for CBD and Other Taupathies	Dr.	Chad	Dickey	University of South Florida, Tampa, FL
2009	The Role of Microglial-Meditated Neuroinflamation in Fronto-Temporal Dementia Tau Pathology	Dr.	Kiran	Bhaskar	Cleveland Clinic, Clevelnd, OH
2009	Eloise H. Troxel Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic, Jacksonville, FL
2008	Unilateral Pedunculopontine Deep Brain Stimulation in PSP	Dr.	Elena	Moro	University of Toronto, Toronto, ON
2008	Noninvasive Cortical Stimulation for Motor and Non-Motor Features of PSP and CBD	Dr.	Alan	Wu	University of California, Los Angeles, CA
2008	Toward a Molecular Understanding of Tau Misfolding	Dr.	Martin	Margittai	University of Denver, Denver, CO
2008	Phenotypic Characterization of Tauopathy Zebrafish	Dr.	Edward	Burton	University of Pittsburgh, Pittsburg, PA
2008	Mapping Progressive Neurodegeneration in PSP using Transcranial Magnetic Stimulation and CSF-Tau	Dr.	David	Williams	Monash University, Australia
2007	Genome-Wide Association Study in PSP	Dr.	Dennis	Dickson	Mayo Clinic College of Medicine, Jacksonville, FL
2007	Genome-Wide Association Study in PSP	Dr.	Rohan	deSilva	Institute of Neurology, UCL,  Queen Square, London
2007	Genome-Wide Association Study in PSP	Dr.	Ulrich	Müller	University Hospital, Giessen, Germany
2007	Genome-Wide Association Study in PSP	Dr.	Hank	Hakonarson	Center for Applied Genomics, Philadelphia, PA
2007	Genome-Wide Association Study in PSP	Dr.	Bernie	Devlin	University of Pittsburgh, Pittsburg, PA
2007	Genome-Wide Association Study in PSP	Dr.	Gerard	Schellenberg	Geriatric Research Education and Clinical Center, Seattle, WA
2007	Longitudinal Prospective PSP Study	Dr.	Irene	Litvan	University of Louisville Health Sciences Center, Louisville, KY
2007	Haplotype regulation of alternative splicing at the MAPT locus	Dr.	Richard	Wade-Martins	University of Oxford, United Kingdom
2007	Unraveling Multi-Protein Chaperone Complexes in PSP and other Tauopathies	Dr.	Chad	Dickey	University of South Florida, Tampa, FL
2007	Genome-Wide Association Study in PSP	Dr.	Ulrich	Muller	University Hospital, Giessen, Germany
2007	Inhibition of Tau Pathology in Transgenic Mouse Models with an Optimized Orally Active Tau Kinase Inhibitor	Dr.	Hanno	Roder	Mayo Clinic, Jacksonville, FL
2007	Strength Training Patients with PSP for Dysphagia	Dr.	Christine	Sapienza	University of Florida, Gainesville, FL
2007	Tau Aggregation in Oligodendrocytes and the Role of Thrombin Signaling	Dr.	Christine	Richter-Landsberg	University of Oldenburg, Germany
2006	Parkin and Tau Mutational Effects on Tangle Formation in PSP	Dr.	Parvoneh	Navas	University of Washington School of Medicine, Seattle, WA
2006	Finemapping of Risk Loci for PSP Identified in a Genome-Wide Scan	Dr.	Michael	Hutton	Mayo Clinic College of Medicine, Jacksonville, FL
2006	Interaction of Neuronal and Glial Tau in a Drosophila Model of Tauopathy	Dr.	Mel	Feany	Brigham and Women’s Hospital, Boston, MA
2006	Hypothesis- Driven Gene Profiling in an Animal Model of PSP	Dr.	Ronald	Klein	LSU Health Sciences Center, Shreveport, LA
2006	Studies of PSA Neuroprotective Role Using Transgenic Mouse Models	Dr.	Stanislav	Karsten	University of California, Los Angeles, CA
2005	AKT-Dependent Signaling in PSP and Transgenic Mouse Model of Tauopathy	Dr.	Hanna	Ksiezak-Reding	Mount Sinai School of Medicine, New York, NY
2005	Eloise H. Troxel Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic, Jacksonville, FL
2005	Inhibiting Transglutaminase Splice Variants for Treatment of PSP	Dr.	Nancy	Muma	Loyola University Chicago, Maywood, IL
2005	Do PSP Associated TAU Polymorphisms Alter the Expression of the TAU Microtubule Binding Domain	Dr.	Hana	Dawson	Duke University Medical Center, Durham, NC
2005	Effect of Coenzyme Q10 in PSP: A Randomized, Multicenter, Placebo-Controlled, Double Blind Study	Dr.	Diana	Apetauerova	Lahey Clinic, Burlington, MA
2005	Proteomics Analysis of a Novel Murine Model of Astrocytic Tau Pathology in PSP	Dr.	Mark	Forman	University of Pennsylvania School of Medicine, Philadelphia, PA
2005	A Zebrafish Model of Tauopathy	Dr.	Edward	Burton	University of Pittsburgh, Pittsburgh, PA
2004	PSP and a Failing Ubiquitin-Proteasome System	Dr.	FW	van Leeuwen	Netherlands Institute for Brain Research, The Netherlands
2004	Identification of Compounds that Modulate Exon 10 Splicing in the Tau Gene	Dr.	Jianhua	Zhou	University of Massachusetts Medical School, Worcester, MA
2004	Proteomis Analysis of Post Mortem PSP Brain	Dr.	Benoit	Giasson	University of Pennsylvania, Philadelphia, PA
2004	Heat Shock Proteins as Inhibitors of Tau Aggregation in Oligodendrocytes	Dr.	Christine	Richter-Landsberg	University of Oldenburg, Germany
2004	Proteomic Analysis of a Transgenic Mouse Model of Tauopathy	Dr.	Shu-Hui	Yen	Mayo Clinic, Jacksonville, FL
2004	Assessment of Tau Protein Isoform profiles in Cerebrospinal Fluid of Tauopathy Patients as a Potential Diagnostic Biomarker	Dr.	Rohan	de Silva,	University College London, London, UK
2001	Eloise H. Troxel Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic, Jacksonville, FL
2003	Parkin Mutations in a Mouse Model of PSP	Dr.	Parvoneh	Navas	University of Washington School of Medicine, Seattle, WA
2003	Correlation of Clinical Severity, Brain Inflammatory Changes & Apparent Water Diffusion Coefficients in PSP & Idiopathic Parkinson’s Disease	Dr.	David	Brooks	Imperial College School of Medicine London, UK
2003	Discovery of Tau Phosphorylation Inhibitors for the Treatment of PSP	Dr.	Kenneth	Kosik	Brigham and Women’s Hospital, Boston, MA
2003	Cystamine, a Transglutaminase Inhibitor, for the Treatment of Tauopathies, Especially in PSP	Dr.	Nancy	Muma	University of Washington,  Seattle, WA
2003	Formation Filamentous Tau Inclusions in Human Cells with Inducible Expression of Tau Proteins	Dr.	Shu-Hui	Yen	Mayo Clinic, Jacksonville, FL
2003	Refining the Genetic and Functional Role of the Tau H1 Haplotype in Neurodegeneration	Dr.	Matt	Farrer	Mayo Clinic, Jacksonville, FL
2003	Aging Effects and Gene Therapy in a Novel Nigrostriatal Degeneration Model	Dr.	Ronald	Klein	LSU Health Sciences Center, Shreveport, LA
2003	Development and Characterization of a Novel Experimental Model of PSP	Dr.	Etienne	Hirsch	Salpetriere, Hospital de la, Paris, France
2003	Genetic Analysis of 17q21 Region Sporadic Tauopathies	Dr.	Alison	Goate	Washington University School of Medicine, St. Louis, MO
2003	Hyperphosphorylation, Tau Filaments and Neurodegeneration in a Transgenic Mouse Model of a Human Tauopathy	Dr.	Maria	Spillantini	University of Cambridge, Cambridge, UK
2003	Identification of Cis-Elements that Regulate Exon 10 Splicing in the Tau Gene	Dr.	Jianhua	Zhou	University of Massachusetts Medical School, Worcester, MA
2003	mRNA Profiling in the Postmortem PSP Brain: Target Identification	Dr.	Sarah	Augood	Massachusetts General Hospital, Boston, MA
2003	Diagnostic Protein Biomarker Discovery in PSP	Dr.	Lap	Ho	University of Washington School of Medicine, St. Louis, MO
2002	A Novel Approach for Neuroprotection in PSP	Dr.	Irene	Litvan	Henry M. Jackson Foundation, Bethesda, MD
2002	Efficacy of Environmental on a Mouse Models of Tauopathy	Dr.	Jada	Lewis	Mayo Clinic College of Medicine, Jacksonville, FL
2002	The Relationship of Guamanian Pigmentary Retinopathy to ALS/PDC of Guam	Dr.	John	Steele	Tamuning, Guam
2002	Prehistory of PSP: Bibliographic Search and Copying	Dr.	Adolfo	Brusa	Ospedalia Galliera, Italy
2002	Cross-Linking of Tau in PSP Neurofibrillary	Dr.	Nancy	Muma	Loyola University Chicago, Maywood, IL
2002	Characterization of Tau Auto-Antibodies in PSP	Dr.	James	Tetrud	The Parkinson’s Institute, Research and Treatment Center, CA
2002	Screening of Tau Mutation in a Unique PSP Family	Dr.	Rong	Chen	The Parkinson’s Institute, Basic Research, Sunnyvale, CA
2002	Analysis of the 17q21 Region in PSP, Tau Gene Analysis in Parkin’s Disease Dementia and in other Atypical Parkinsonims	Dr.	Eduardo	Tolosa	Neurology Service, Hospital Clinic, Barcelona, Spain
2002	Cortial and Striatal Cholinergic Receptor Subtypes in PSP, Alzheimer’s Disease and Dementia with Lewy Bodies	Dr.	David	Burn	Newcastle General Hospital, Regional Neuroscience Centre, UK
2002	Glial Tau Aggregates in PSP and Human Cultured Cells	Dr.	Hanna	Ksiezak-Reding	Mount Sinai School of Medicine, New York, NY
2002	Development of a Measure of Health-Related Quality of Life PSP	Dr.	Anette	Schrag	University College London, London, UK
2006	Eloise H. Troxel Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic, Jacksonville, FL
2001	Finding the Cause and Effect of a Bioenergetic Defect in PSP	Dr.	David	Albers	Cornell University, Weill Medical College, New York, NY
2001	Interaction of Parkin Protein with Abnormal Tau	Dr.	Paul	Fishman	University of Maryland School of Medicine, Baltimore, MD
2001	Characterization of the Molecular Mechanisms Leading to PSP	Dr.	Justo	Garcia de Yebenes	Fundacion Jimenez Diaz, Madrid, Spain
2000	Regulation of Human Tau Gene Expression and it’s Role in PSP	Dr.	Jane	Wu	Washington University School of Medicine, St. Louis, MO
2001	Tau Auto-Antibody Production in PSP	Dr.	James	Tetrud	The Parkinson’s Institute, Research and Treatment Center, , CA
2001	Mechanisms Regulating Neurofibrillary Tangle Formation in PSP	Dr.	Nancy	Muma	University of Washington, Seattle, WA
2001	Comparison of Region Specific MRNA Expression Profiles of PSP Brains with those of Alzheimer, FTDP-17, Pick Disease & Non Affected Brains, using DNA Microarray Technology	Dr.	Vincenzo	Bonifati	Erasmus University Rotterdam, The Netherlands
2001	mRNA Profiling in the Postmortem PSP Brain: Identifying Abnormal Signaling Pathways	Dr.	Sarah	Augood,	Massachusetts General Hospital, Boston, MA
2001	Dopa-resistant Parkinsonism in Guadeloupe: Evaluation of Isoquinolines Derivates and Acetogenines Toxicity in Rats	Dr.	Dominique	Caparros-Lefebvre	University Hospital, Guadeloupe, France
2000	Effect of Lipoperxidation on cdk5 Activity and Tau Protein Aggregation: A Model of PSP Pathogenesis	Dr.	Massimo	Tabaton	University of Genova, Department of Neurosciences, Italy
2000	Are Matrix Metalloproteinases Involved in the Pathogenesis of PSP?	Dr.	David	Albers	Cornell University, Weill Medical College, New York, NY
2001	Regulation of Human Tau Gene Expression and it’s Role in PSP	Dr.	Jane	Wu	Washington University School of Medicine, St. Louis, MO
2000	Environmental Factors and Detoxification Mechanisms in PSP	Dr.	Rosemary	Waring	The University of Birmingham, Birmingham, UK
1999	Mutational Analysis of the Tau Gene in PSP	Dr.	Joseph	Higgins	New York State Dept. of Health, New York, NY
1999	Ultrastructural and Biochemical Hetergeneity of Paired Helical Filaments in PSP	Dr.	Hanna	Ksiezak-Reding	Mount Sinai School of Medicine, New York, NY
1999	Are Impairments of Energy Metabolism Contributory in PSP?	Dr.	Flint	Beal, M. Flint, MD	Cornell University, Weill Medical College, New York, NY
1999	Activity and Expression of Antioxidant Enzymes in the PSP Brain	Dr.	Sarah	Augood	Massachusetts General Hospital, Boston, MA
1999	Problems of Cell Death in PSP	Dr.	Kurt	Jellinger	University of Vienna School of Medicine, Austria
1999	Identification of the PSP Gene	Dr.	Parvoneh	Navas	University of Washington, Seattle, WA
1999	Role of the Thalmus in PSP and Parkinson’s Disease	Dr.	Jasmine	Henderson	Prince of Wales Medical Research Institute, Randwick, Australia
1999	Is Brain Oxidative Stress & Damage Characteristic of PSP?	Dr.	Stephen	Kish	Centre for Addiction & Mental Health, Toronto, ON, Canada
1999	Mechanisms of Neurofibrillary Tangle Formation in PSP	Dr.	Nancy	Muma	Loyola University Chicago, Maywood, IL
1999	Synaptic Protein Loss and Alterations in Growth Inhibitory Factors as a Biological Foundation of Behavioural Changes & Cognitive Decline in PSP	Dr.	Elizabeth	Mukaetova-Ladinska	University of Newcastle upon Tyne, UK
1998	Neuropathological Grading Scale for PSP	Dr.	Mark	Becher	University of New Mexico, Health Science Center, Albuquerque, NM
1998	Neuroanatomical Basis for PSP Eyelid Motor Dysfunction	Dr.	Mark	LeDoux	University of Tennessee, Memphis, TN
1998	Mitochondria in PSP	Dr.	Russell	Swerdlow	University of Virginia School of Medicine, Charlottesville, VA
1998	Tau Gene Mutations in PSP	Dr.	Joseph	Higgins	Laboratory of Clinical Neurogenetics, Wadsworth Center, Albany, NY
1998	Oxidative Mechanisms in PSP	Dr.	David	Albers	Massachusetts General Hospital, Neurology Dept., Boston, MA
1998	Molecular Studies of the Tau Gene in PSP	Dr.	William	Johnson	Robert Wood Johnson Medical School, New Brunswick, NJ
1998	Potential Role of Mitochondrial Defects in PSP	Dr.	Flint	Beal	Cornell University, Weill Medical College, New York, NY
1998	Trial of Donepezil HCL in PSP Patients	Dr.	Irene	Litvan	Henry M. Jackson Foundation, Bethesda, MD
1998	Establishment of a PSP Brain Bank	Dr.	Dennis	Dickson	Mayo Clinic, Jacksonville, FL
1997	Haplotype Relative Risk Analysis in PSP	Dr.	Lawrence	Golbe	Robert Wood Johnson Medical School, New Brunswick, NJ
1997	The History of PSP	Dr.	Adolfo	Brusa	Corso A. Saffi, Genoa, Italy
1997	Reaction Time and Acoustic Startle in Patients with PSP, Multi-System Atrophy, Barcelona and Parkinson’s Disease	Dr.	Josep	Valls-Sole	Hospital Clinic, Barcelona, Spain
1997	Linkage Analysis in Familial PSP (To Perform Linkage Analysis in a Large Spanish Family with PSP)	Dr.	Justo	Garcia de Yebenes	Universidad Autonoma de Madrid, Madrid, Spain
1997	Ferritin is Associated with the Aberant Tau Filaments Present in PSP	Dr.	Jesus	Avila	Centro De Biologica Molecular, Madrid, Spain
1997	Genetics and Environmental Studies of Bodig and Lytico in Villages of Southern Guam	Dr.	John	Steele	Tamuning, Guam
1997	Presence and Amount of Glycation & Oxidation Markers in PSP	Dr.	Massimo	Tabaton	University of Genova, Italy